CAR T-cell Therapy
TIL + Pembrolizumab for Melanoma
Recruiting1 awardPhase 2
Bethesda, Maryland
This trial is testing if adding the drug pembrolizumab to cell therapy, which takes young tumor infiltrating lymphocytes (TIL) cells from a person's tumors and grows them in a lab, is safe and effective to shrink melanoma tumors.
Tyrosine Kinase Inhibitor
Entrectinib for Solid Tumors
Recruiting1 awardPhase 2
Phoenix, Arizona
This trial is testing a new drug, entrectinib, for patients with different types of solid tumors that have a gene fusion. Patients will be assigned to different groups depending on their tumor type and gene fusion.
Popular Filters
Trials for Squamous Cell Carcinoma Patients
Cancer Vaccine
WDVAX Vaccine for Melanoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is looking at a new vaccine for melanoma, which is still being studied. The goal is to find out if the vaccine is safe and effective, as well as the appropriate dose. The vaccine contains the patient's own tumor cells, which have been killed and combined with other proteins.
Radiation Therapy
IMRT vs Proton Radiation Therapy for Sinonasal Cancer
Recruiting1 award
Boston, Massachusetts
This trial will test whether IMRT or proton radiation therapy improves local control rates and lowers toxicity compared to conventional radiation therapy in the treatment of locally advanced sinonasal malignancy.
Alkylating Agent
Veliparib + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
MEK Inhibitor
AZD6244 + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Detroit, Michigan
This study is evaluating whether a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated
Trials for Skin Cancer Patients
Cancer Vaccine
WDVAX Vaccine for Melanoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is looking at a new vaccine for melanoma, which is still being studied. The goal is to find out if the vaccine is safe and effective, as well as the appropriate dose. The vaccine contains the patient's own tumor cells, which have been killed and combined with other proteins.
MEK Inhibitor
AZD6244 + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Detroit, Michigan
This study is evaluating whether a combination of AZD6244 given orally twice a day with standard doses of selected chemotherapies will be safe and tolerable for cancer patients with advanced solid tumors. The highest tolerated dose of AZD6244 in combination with selected chemotherapies will be evaluated
Chemotherapy
Adoptive Cell Transfer + Immunotherapy for Melanoma
Recruiting2 awardsPhase 2
Houston, Texas
This trial is studying three different combinations of treatment as compared to treatment with T cells and high dose IL-2 alone in order to find which combination is the most effective in treating patients with melanoma.
Trials for Metastatic Patients
Hu3F8 PET Imaging for Brain Cancer
Recruiting1 award
New York, New York
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Cancer Vaccine
WDVAX Vaccine for Melanoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is looking at a new vaccine for melanoma, which is still being studied. The goal is to find out if the vaccine is safe and effective, as well as the appropriate dose. The vaccine contains the patient's own tumor cells, which have been killed and combined with other proteins.
Radiation Therapy
IMRT vs Proton Radiation Therapy for Sinonasal Cancer
Recruiting1 award
Boston, Massachusetts
This trial will test whether IMRT or proton radiation therapy improves local control rates and lowers toxicity compared to conventional radiation therapy in the treatment of locally advanced sinonasal malignancy.
Alkylating Agent
Veliparib + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
Trials for PD-L1 Positive Patients
Kinase Inhibitor
Trametinib + Ceritinib for Melanoma
Recruiting1 awardPhase 1
Tampa, Florida
This trial is testing a new combination therapy for melanoma that has progressed despite other treatments. The goal is to see if this new combination is more effective than current treatments and has fewer side effects.
Monoclonal Antibodies
GEN1042 for Advanced Cancers
Recruiting1 awardPhase 1 & 2
New Haven, Connecticut
This trial is testing a new drug called GEN1042 to see if it can help treat advanced cancer. It focuses on patients whose cancer has spread or is hard to treat. The goal is to find out if GEN1042 can safely reduce or stop tumor growth.
Procedure
ENB003 + Pembrolizumab for Cancer
Recruiting2 awardsPhase 1 & 2
Houston, Texas
This trial is testing a new cancer drug, ENB003, to see if it is safe and effective. The study will first test the drug on a small group of people to see what doses are safe. Then the study will be expanded to include more people with different types of cancer.
Trials for BRAF Positive Patients
Kinase Inhibitor
Trametinib + Ceritinib for Melanoma
Recruiting1 awardPhase 1
Tampa, Florida
This trial is testing a new combination therapy for melanoma that has progressed despite other treatments. The goal is to see if this new combination is more effective than current treatments and has fewer side effects.
Kinase Inhibitor
Triple Drug Therapy for Advanced Melanoma
Recruiting2 awardsPhase 3
Tucson, Arizona
This trial is testing a combination of three drugs to treat advanced skin cancer in patients with a specific genetic mutation. One drug helps the immune system fight cancer, while the other two stop cancer cells from growing. The study aims to see if this combination is safe and effective.
Kinase Inhibitor
LXH254 Combinations for Melanoma
Recruiting1 awardPhase 2
Los Angeles, California
This trial is testing a new medication called LXH254, used in combination with other treatments, for people with a type of skin cancer that can't be removed by surgery and has spread. These patients have already tried other treatments. LXH254 works by blocking signals in the cancer cells to slow or stop their growth.
Phase 3 Trials
Radiation
IGIMRT Dosing Schedules for Cancer Spread to Bone/Spine
Recruiting2 awardsPhase 3
San Francisco, California
This trial is studying two ways of giving high-dose radiation for treatment of cancer that has spread to bone, the spine, soft tissue, or lymph nodes. One way is 27 Gy in three fractions (3 days) and the other is 24 Gy in one fraction (1 day).
Checkpoint Inhibitor
Pembrolizumab for High-risk Stage II Melanoma
Recruiting1 awardPhase 3
Tucson, Arizona
This trial will evaluate the safety and efficacy of pembrolizumab compared to placebo in participants with surgically resected high-risk Stage II melanoma. The primary hypothesis is that pembrolizumab increases recurrence-free survival.
Checkpoint Inhibitor
Relatlimab + Nivolumab for Advanced Melanoma
Recruiting1 awardPhase 2 & 3
Tucson, Arizona
This trial is testing if using two medications together (relatlimab and nivolumab) is better than using just one (nivolumab) for treating a type of skin cancer that can't be removed by surgery or has spread. The drugs help the immune system to better recognize and attack cancer cells.
Nivolumab for Melanoma Prevention
Recruiting1 awardPhase 3
Birmingham, Alabama
This trial is testing if nivolumab can help prevent melanoma from returning in patients who have had their cancer surgically removed but are at high risk for it coming back. Nivolumab boosts the immune system to fight any remaining cancer cells. Nivolumab is used for the treatment of malignant melanoma and has shown promising anticancer activity in various cancers.
Kinase Inhibitor
Triple Drug Therapy for Advanced Melanoma
Recruiting2 awardsPhase 3
Tucson, Arizona
This trial is testing a combination of three drugs to treat advanced skin cancer in patients with a specific genetic mutation. One drug helps the immune system fight cancer, while the other two stop cancer cells from growing. The study aims to see if this combination is safe and effective.
Trials With No Placebo
Hu3F8 PET Imaging for Brain Cancer
Recruiting1 award
New York, New York
This trial is studying how a special protein called Hu3F8 moves through the body and targets tumors. Hu3F8 is designed to attach to tumor cells, helping the immune system recognize and destroy them. The study focuses on patients with tumors to see how well this protein works in attacking cancer cells.
Cancer Vaccine
WDVAX Vaccine for Melanoma
Recruiting1 awardPhase 1
Boston, Massachusetts
This trial is looking at a new vaccine for melanoma, which is still being studied. The goal is to find out if the vaccine is safe and effective, as well as the appropriate dose. The vaccine contains the patient's own tumor cells, which have been killed and combined with other proteins.
Radiation Therapy
IMRT vs Proton Radiation Therapy for Sinonasal Cancer
Recruiting1 award
Boston, Massachusetts
This trial will test whether IMRT or proton radiation therapy improves local control rates and lowers toxicity compared to conventional radiation therapy in the treatment of locally advanced sinonasal malignancy.
Alkylating Agent
Veliparib + Chemotherapy for Advanced Cancer
Recruiting1 awardPhase 1
Duarte, California
This trial is studying the side effects and best dose of veliparib when given with paclitaxel and carboplatin to treat patients with solid tumors that have spread or cannot be removed by surgery and have liver or kidney dysfunction.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.